Orgenesis Inc ORGS:NASDAQ

Last Price$2.42NASDAQ Closing Price as of 4:00PM ET 6/30/22

Today's Change-0.10(3.97%)
Bid (Size)$2.36 (5)
Ask (Size)$2.42 (6)
Day Low / High$2.26 - 2.50
Volume17.0 K
 

View Biotechnology IndustryPeer Comparison as of 06/30/2022

 

Orgenesis Inc ( NASDAQ )

Price: $2.42
Change: -0.10 (3.97%)
Volume: 17.0 K
4:00PM ET 6/30/2022
 
 

Equillium Inc ( NASDAQ )

Price: $2.04
Change: +0.24 (13.33%)
Volume: 28.0 K
4:00PM ET 6/30/2022
 
 

ImmuCell Corp ( NASDAQ )

Price: $8.69
Change: +0.42 (5.08%)
Volume: 5.5 K
4:00PM ET 6/30/2022
 
 

Syros Pharmaceuticals Inc ( NASDAQ )

Price: $0.96
Change: +0.003 (0.36%)
Volume: 201.2 K
4:00PM ET 6/30/2022
 
 

Magenta Therapeutics Inc ( NASDAQ )

Price: $1.20
Change: +0.04 (3.45%)
Volume: 56.0 K
4:00PM ET 6/30/2022
 

Read more news Recent News

-- Earnings Flash (ORGS) ORGENESIS Posts Q1 EPS $0.16
7:01AM ET 5/24/2022 MT Newswires

...

-- Earnings Flash (ORGS) ORGENESIS Posts Q1 Revenue $7.2M
7:01AM ET 5/24/2022 MT Newswires

...

Orgenesis Launches $14.8 Million Private Placement
7:42AM ET 3/31/2022 MT Newswires

Orgenesis (ORGS) said Thursday that it agreed to sell 4,933,333 shares of common stock in a private placement at $3 per share and warrants to purchase up...

Orgenesis, Theracell Joint Venture to Receive up to $36 Million From Greek Government; Shares Rise Pre-Bell
8:24AM ET 11/29/2021 MT Newswires

Orgenesis (ORGS) said Monday that its joint venture with Theracell Advanced Biotechnology in Greece has been designated a "Priority Investment of Strategic...

Company Profile

Business DescriptionOrgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing and provision of technologies and services in the cell and gene therapy industry. It operates through the Contract Development and Manufacturing Organization (CDMO) and Point-Of-Care Cell Therapy (POC) segments. The CDMO segment, through MaSTherCell, consists of services from cell therapy development through cell therapy manufacturing and companies that provide an end-to-end solution. The POC segment provides a multitude of cell therapies including, but not limited to, cell-based immunotherapies, therapeutics for metabolic diseases, neurodegenerative diseases and tissue regeneration. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD. View company web site for more details
Address20271 Goldenrod Lane
Germantown, Maryland 20876
Phone+1.480.659.6404
Number of Employees231
Recent SEC Filing06/16/20224
Chairman, President & Chief Executive OfficerVered Caplan
Chief Financial Officer, Secretary & TreasurerNeil Reithinger
Chief Scientific OfficerSarah Ferber
Medical DirectorHeiko von der Leyen

Company Highlights

Price Open$2.50
Previous Close$2.52
52 Week Range$1.77 - 5.49
Market Capitalization$60.1 M
Shares Outstanding24.8 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.90
Beta vs. S&P 500N/A
Revenue$18.7 M
Net Profit Margin-65.55%
Return on Equity-52.11%

Analyst Ratings as of 04/19/2021

Buy
1
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset